BioCell Collagen supports joint health, human trial finds

In a study of 80 subjects, researchers found that people experienced significant improvement in joint discomfort levels after taking BioCell Collagen.

In results of a multi-center, double-blind, placebo-controlled human clinical study published by the prestigious Journal of Agriculture and Food Chemistry, researchers found that people experienced significant improvement in their joint discomfort levels, and ability to participate in everyday activities, after taking BioCell Collagen.

BioCell Collagen contains highly bioavailable forms of the major constituents of human joints: collagen type II, hyaluronic acid and chondroitin sulfate. There are more than 14 different types of collagen found in the body. Collagen type II is the main structural building block of soft connective tissue and joint cartilage. Previous studies have demonstrated that BioCell Collagen is effectively absorbed into the bloodstream, and indicate that hydrolyzed collagen-derived peptides are deposited into the joint cartilage to protect and to stimulate the chondrocytes to produce novel collagen type II and other molecules essential for the cartilage structure.

“This ingredient has a lower molecular weight than other forms of joint supplements, which appears to be an important reason for its effectiveness,” comments Jerome Stenehjem, MD, School of Medicine, University of California at San Diego, a principle study investigator. “It is possible that nutrients such as those found in this patented supplement may improve the quality of the joint fluid, thereby supporting better joint health.”

Clinical trial details
This recent study involved 80 subjects. They received either 1 gram twice daily of BioCell Collagen or a placebo for 70 days. The collagen group experienced a significant improvement. All primary endpoint were met for statistical significance. The percentage of the subjects who experienced at least 30 percent improvement was 40 percent in the BioCell Collagen group and only 3 percent in the placebo. BioCell Collagen was well tolerated by the subjects in the clinical trial.

“This was the largest randomized controlled human study to date of BioCell Collagen, and it confirms previous studies that demonstrated similar effectiveness and safety,” stated Stenehjem.

Added study investigator Alexander G. Schauss, PhD, FACN, Senior Director of AIBMR Life Sciences, “This was a well-designed study published by one of the most recognized scientific journals in the world. We are pleased that results build on the substantial body of evidence indicating BioCell Collagen’s potential to make a difference in people’s lives.”

To view the abstract of the clinical trial, click here.


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.